![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GILEAD BUYING CORUS PHARMA FOR $365M
GILEAD BUYING CORUS PHARMA FOR $365M
July 20, 2006
Gilead Sciences Inc., which is based in Foster City, Calif., will pay $365 million for Corus Pharma. The deal for the privately held Seattle company, which makes specialty products for respiratory and infectious diseases, is set to close by the end of the month, Gilead said Wednesday. Also, Gilead has reached an agreement with Novartis Vaccine and Diagnostics Inc., whereby Novartis will end its litigation against Corus for an undisclosed payment.
UPI
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct